OLMA — Olema Pharmaceuticals, Inc. stock price, charts and financials
QT67Olema Pharmaceuticals, Inc.Olema Pharmaceuticals, Inc. (NASDAQ: OLMA) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
11.28
-0.17-1.48%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 41.23% | Shs Outstand | 87.35M | Perf Week | -2.14% |
| Market Cap | 1.00B | Forward P/E | - | EPS next Y | -2.40 | Insider Trans | -0.18% | Shs Float | 70.82M | Perf Month | -5.22% |
| Enterprise Value | 948.54M | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 21.33% | Perf Quarter | -20.54% |
| Income | -157.32M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 10.66 | Perf Half Y | -56.06% |
| Sales | 0.00 | P/B | 2.45 | EPS next Y | -8.51% | ROA | -34.89% | Short Interest | 15.10M | Perf YTD | -54.20% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -45.95% | 52W High | 35.72 -68.42% | Perf Year | 124.51% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -41.66% | 52W Low | 4.40 156.15% | Perf 3Y | 30.41% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 5.55% 5.51% | Perf 5Y | -55.65% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 8.18% | Oper. Margin | 0.00% | ATR (14) | 0.69 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 10.88 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 47.33 | Recom | 2.00 |
| Dividend Gr. 3/5Y | - | Current Ratio | 10.88 | EPS Q/Q | -44.44% | SMA20 | -2.92% | Beta | 1.99 | Target Price | 40.33 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -0.72% | Rel Volume | 0.49 | Prev Close | 11.45 |
| Employees | 137 | LT Debt/Eq | 0.00 | Earnings | Aug 10 | SMA200 | -34.39% | Avg Volume | 1.44M | Price | 11.28 |
| IPO Date | Nov 19, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 2.02% - | Net Debt/EBITDA | 0.28 | Volume | 709,777 | Change | -1.48% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-13-26 | Reiterated | Guggenheim | Buy | $40 → $35 |
| Mar-09-26 | Reiterated | HC Wainwright & Co. | Buy | $45 → $38 |
| Feb-10-26 | Initiated | Stifel | Buy | |
| Jan-07-26 | Initiated | Piper Sandler | Overweight | $40 |
| Jan-07-26 | Reiterated | UBS | $45 | |
| Dec-11-25 | Reiterated | HC Wainwright & Co. | Buy | $36 → $45 |
| Dec-11-25 | Reiterated | Oppenheimer | Outperform | |
| Dec-11-25 | Reiterated | Goldman Sachs | Buy | $26 → $38 |
| Dec-10-25 | Reiterated | Jefferies | $30 → $43 | |
| Nov-21-25 | Reiterated | Goldman Sachs | Buy | $27 → $26 |
Latest News
Jul-27-26
Jun-30-26
Company
Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Selling, General and Administrative Excl. Other | 21 | 18 | 19 | 25 | 20 | 8 | 0 | 0 | |
| Research and Development | 158 | 125 | 86 | 82 | 51 | 14 | 4 | 2 | |
| Other Operating Expense | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | -179 | -142 | -105 | -107 | -71 | -22 | -4 | -2 | |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 1 | — | 0 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 16 | 13 | 8 | 2 | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | -162 | -129 | -97 | -105 | -71 | -22 | -4 | -2 | |
| Income Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Consolidated Net Income | -162 | -129 | -97 | -105 | -71 | -22 | -4 | -2 | |
| Net Income From Continuing Operations | -162 | -129 | -97 | -105 | -71 | -22 | -4 | -2 | |
| Net Income | -162 | -129 | -97 | -105 | -71 | -22 | -4 | -2 | |
| EPS (Recurring) | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 | -0.11 | -0.16 | |
| EPS (Basic, Before Extraordinaries) | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 | -0.11 | -0.16 | |
| EPS (Diluted) | -1.87 | -2.20 | -2.14 | -2.62 | -1.79 | -0.58 | -0.11 | -0.16 | |
| EBITDA | -162 | -129 | -96 | -104 | -71 | -22 | -4 | -2 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 87 | 59 | 45 | 40 | 40 | 39 | 40 | 14 | |
| Market Capitalization | 2,175 | 344 | 631 | 98 | 374 | 1,875 | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Harmon Cyrus | Director | Jul 24 '26 | Sale | 11.71 | 12,500 | 146,425 | 702,770 | Jul 27 |
| Harmon Cyrus | Director | Jul 23 '26 | Sale | 11.58 | 12,500 | 144,738 | 715,270 | Jul 27 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 04 '26 | Sale | 24.25 | 25,000 | 606,353 | 0 | Mar 05 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 04 '26 | Option Exercise | 4.37 | 25,000 | 109,250 | 25,000 | Mar 05 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 03 '26 | Sale | 23.01 | 15,000 | 345,150 | 0 | Mar 05 |
| Mitchell Shawnte | CHIEF LEGAL OFFICER | Mar 03 '26 | Option Exercise | 4.37 | 15,000 | 65,550 | 15,000 | Mar 05 |
| Harmon Cyrus | Director | Jan 20 '26 | Sale | 26.88 | 10,000 | 268,800 | 727,770 | Jan 21 |
| Harmon Cyrus | Director | Jan 14 '26 | Sale | 29.12 | 3,489 | 101,600 | 737,770 | Jan 16 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Jan 15 '26 | Sale | 28.73 | 100,000 | 2,873,000 | 139,727 | Jan 15 |
| Kovacs Shane William Charles | CH. OPERATING & FINANCIAL OFF. | Jan 13 '26 | Sale | 28.01 | 3,822 | 107,054 | 239,727 | Jan 15 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14 '26 | Sale | 28.87 | 50,000 | 1,443,651 | 542,761 | Jan 14 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 14 '26 | Option Exercise | 4.87 | 50,000 | 243,500 | 592,761 | Jan 14 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13 '26 | Sale | 27.60 | 50,000 | 1,380,178 | 542,761 | Jan 14 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 13 '26 | Option Exercise | 4.87 | 50,000 | 243,500 | 100,000 | Jan 14 |
| Myles David C. | CH. DISCOV. & NON-CLIN DEV OFF | Jan 12 '26 | Sale | 28.34 | 10,000 | 283,400 | 144,846 | Jan 14 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.